PET imaging studies show enhanced expression of mGluR5 and inflammatory response during progressive degeneration in ALS mouse model expressing SOD1-G93A gene by unknown
RESEARCH Open Access
PET imaging studies show enhanced
expression of mGluR5 and inflammatory
response during progressive degeneration
in ALS mouse model expressing SOD1-
G93A gene
Anna-Liisa Brownell1*, Darshini Kuruppu2, Kun-Eek Kil1, Kimmo Jokivarsi1, Pekka Poutiainen1, Aijun Zhu1
and Michelle Maxwell3
Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative motor neuron disorder.
Genetic studies have linked mutation of the gene SOD1 to ALS pathology as well as several other pathological
processes including modulation of glutamatergic function and inflammatory processes. Since therapeutic
approaches for ALS are focused on glutamatergic function, we investigated modulation of glutamate transport
based on its receptor function as well as excitotoxicity-induced inflammatory response.
Methods: In vivo positron emission tomography (PET) imaging studies of metabotropic glutamate receptor
subtype 5 (mGluR5) using [18F]FPEB ([18F]3-fluoro-5-(2-pyridylethynyl)benzonitrile) and inflammatory response
using [11C]PBR28 (peripheral benzodiazepine receptor ligand 28) were done in an early and a late phase of
neurodegeneration in four ALS mice expressing SOD1-G93A gene and four control base mice (C57/BL6).
Accumulation of [18F]FPEB and [11C]PBR28 were quantitated in several brain areas and spinal cord to determine
degeneration-induced modulation. The studies were completed with immunohistochemical analyses of mGluR5
and inflammatory response.
Results: These studies showed enhanced binding potential of [18F]FPEB in several brain areas including striatum,
hippocampus, and frontal cortex. In the whole brain, the binding potential increased 49 ± 9 % from base mice to
ALS-type mice and further enhanced 23 ± 4 % during disease progression. Also, in the spinal cord 6–22 %,
enhanced accumulation of [18F]FPEB was observed during progression of the disease. The accumulation of
[11C]PBR28 increased by 110 ± 33 % in the whole brain during progression of the disease indicating significant
inflammatory process. [11C]PBR28 accumulation enhanced 89–264 % in the spinal cord and 204 % in the lungs.
The end point immunohistochemical analyses verified the enhanced mGluR5 expression and inflammation.
Conclusions: These results confirm the role of glutamate and inflammation in ALS-type pathology. These data also
support the hypothesis that excessive glutamate may contribute to inflammation in the chronic neurodegenerative
processes in ALS.
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Background
Amyotrophic lateral sclerosis (ALS) is a devastating
neuromuscular disorder without known cause or cura-
tive treatment. The pathological processes linked to ALS
are formation of intraneuronal aggregates of neurofila-
ment [1]; microglia mediated neurotoxicity as a result of
enhanced inflammatory response [2–5]; glutamatergic
neurotoxicity as a result of deficit in glutamate trans-
porter or receptor function [6–11]; and mitochondrial
dysfunction as a result of failure in oxidative metabolism
[12, 13] and superoxide dismutase-1 (SOD1) mediated
neurotoxicity, which is associated to gene mutation and
found in familiar form of ALS [14, 15]. Altogether, ALS
is a multimodal disorder and it is not yet known what
mechanism ignites the fast progression of the disease.
For the treatment of ALS, the Food and Drug Admin-
istration has approved one drug, riluzole, which inhibits
glutamate release. Another drug, ceftriaxole, which be-
longs to penicillin family, increases glutamate transport
and is used in clinical trials [16, 17]. Thus, glutamate-
related research is an essential part for development of
diagnosis and treatment of ALS. It has been shown that
ALS patients have enhanced glutamate levels in serum
and spinal cord. Extracellular glutamate can induce
neurotoxicity by either increasing neuronal sodium and
chloride influx during depolarization or increasing cal-
cium influx. Increased calcium influx may lead to activa-
tion of several calcium-dependent enzymes with end point
damage in DNA and mitochondrial dysfunction [1, 7]. It
is noticeable that neurotransmitter glutamate does not
cross blood-brain barrier but its function can be investi-
gated based on its receptors.
Metabotropic glutamate receptors (mGluRs) have vari-
ous physiological functions in the central nervous system
by affecting on several intracellular signal transduction
mechanisms through G-protein [18, 19]. A large amount
of pharmacological agents acting on metabotropic glutam-
ate receptors have appeared in literature. Starting from
1996 [20], several non-competitive negative, positive, and
neutral allosteric modulators have been developed as
mGluR ligands [21, 22]. These ligands modulate mGlu re-
ceptor activity by binding to allosteric binding sites that
are located in the seven strand transmembrane domains.
The allosteric binding site is structurally distinct from the
classical agonist or antagonist orthosteric binding site [23].
The glial cells that usually support and nourish neigh-
boring neurons in the nervous system can become over-
active in certain conditions. If glia becomes too
activated, it can damage the tissue. When glutamate is
taken up into glial cell by excitatory amino acid trans-
porters, it is not reused directly but converted to glu-
tamine and stored in vesicles. Subsequently, these
vesicles are released from glial cells, and glutamine is
transported back into presynaptic neuron and converted
back to glutamate [23]. Excitotoxicity, which is mediated
by the excessive activation of glutamate receptors, has
been implicated in the pathogenesis of ALS. Aronica
et al. [24] demonstrated with immunocytochemical ana-
lyses that mGluR5 expression was high in neuronal cell
throughout the human spinal cord with the highest ex-
pression in ventral horn neurons. Regional differences in
immunoreactivity were observed in ALS compared to
control studies. Especially, mGluR5 expression was in-
creased in reactive glial cell in both gray (ventral horn)
and white matter of ALS spinal cord [24]. Upregulation
of mGluRs in reactive astrocytes may represent a critical
mechanism for modulation of glial function and changes
in glial-neuronal communication in chronic neurodegen-
eration [24]. Activated microglial cells can play a major
role in the neuronal loss after a lesion or an insult, such
as neurotoxin exposure [25]. There is increasing evi-
dence that inflammation accompanies the death of
motor neurons in ALS [26].
We have developed several allosteric modulators to
image metabotropic glutamate subtype receptors 5
(mGluR5s) [27–29] and characterized their in vivo dy-
namic biodistribution and functional binding properties
in different experimental animal models including ALS
mouse model using in vivo microPET imaging studies
[30–32]. Here, we report preliminary positron emission
tomography (PET)/computerized tomography (CT) im-
aging studies of modulation of mGluR5 expression and
CNS inflammation during progressive degeneration in
ALS mouse model carrying SOD1-G93A gene.
Methods
In vivo PET imaging studies
All animal studies were approved by the subcommittee
on research animals of the Massachusetts General Hos-
pital and Harvard Medical School and carried out by the
guidance of the National Institute of Health Guide for
the Care and Use of Laboratory Animals.
In vivo PET imaging studies were conducted in four base
mice (C57/BL6) and four transgenic mouse model of ALS
expressing human gene, SOD1-G93A (superoxide dismut-
ase 1-glycine 93S mutation), to investigate synaptic glu-
tamatergic function and inflammatory response during
progression of the disease. The used PET imaging ligand
for mGluR5, [18F]FPEB ([18F]3-fluoro-5-(2-pyridylethynyl)-
benzonitrile) [27] is developed by our team and it is pres-
ently in a routine production. Imaging of inflammatory
response was done using [11C]PBR28 (peripheral benzodi-
azepine receptor ligand 28), an imaging ligand for translo-
cator protein 18kDA (TSPO) which is a biomarker for
inflammation and activated microglia.
For imaging studies, animals were anesthetized with iso-
flurane/nitrous oxide/oxygen (1–1.5 % isoflurane at 1 l/min
flow) and placed on the imaging table. Catheterization of
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tail vein was done for the administration of the radiolabeled
ligands. The animal head was secured in a plexiglass
custom-made head holder equipped with ear and mouth
bars designed to ensure reproducible head positioning.
Level of anesthesia and vital signs was monitored through-
out the imaging procedures using the physiological moni-
toring system included to the imaging device (Triumph II,
Trifoil Imaging, Inc).
After the animal was adjusted into the imaging pos-
ition, a computerized tomography (CT) imaging was
done before administration of the radioactivity to obtain
high-resolution anatomical information and data for at-
tenuation correction. Radiolabeled ligand, [18F]FPEB or
[11C]PBR28, (0.1–0.2 mCi, specific activity of 1900 mCi/
μmol for [18F]FPEB or 0.2–0.3 mCi of [11C]PBR28) was
injected into the tail vein. The radioactivity was diluted
into the saline in portion 1 to 10 before the injection to
decrease the ethanol concentration that was 10 % after
the production of the ligand. Dynamic volumetric imaging
data were acquired for 60 min after the administration of
the radiolabeled ligand. Imaging data were corrected for
uniformity, sensitivity, scatter, attenuation, decay, and ac-
quisition time. PET images were reconstructed using a
volumetric maximum likelihood estimation method
(three-dimensional maximum likelihood estimation method)
with 30 iterations (the software provided by the manufac-
turer of the scanner). The regions of interest including stri-
atum, frontal cortex, hippocampus, cerebellum, whole
brain area, and several areas in spinal cord were drawn on
all coronal and axial levels, visualized in the fused PET-CT
images. Activity per unit volume, percent activity of injected
dose, and the ligand concentration were calculated.
Studies of mGluR5 expression with [18F]FPEB were
done at first and followed by studies of inflammation
with [11C]PBR 2 days later. To follow the progressive de-
generation, the PET imaging studies were repeated
2 weeks later. The experimental studies of neurodegen-
eration were completed with immunohistological studies
(IHS) including expression of mGluR5 and inflammation
with IBA1.
Kinetic analysis of [18F]FPEB data obtained from brain
was done using the Pmod software package (Pmod
Technologies, Zurich, Switzerland) to determine regional
values for binding potential [29, 33, 34]. Since rodent cere-
bellum does not express mGlu5 receptors or the expression
is minimal, the input function can be processed from the
data obtained from cerebellum in calculating regional maps
for binding potential [27, 29]. Concerning [11C]PBR28,
cerebellum cannot be used as a reference area, since in-
flammation is not brain area specific. For that reason, the
accumulation of [11C]PBR28 was expressed as percent of
the injected dose per cm3 (%id/cm3).
Scoring of the progressive degeneration was deter-
mined according to the following criteria: if the hind legs
were fully extended away from lateral midline when
mouse was suspended by its tail and the mouse could
hold this for 2 s when suspended 2–3 times the score
was 1 and if two toes curled under at least twice during
walking of 12 in. or any part of foot was dragging along
cage bottom/table the score was 3. The scoring model
was modified from the behavioral model of Knippenberg
et al. [35] in ALS mice.
Statistical analyses
Statistical analyses between the control and ALS mice as
well as during progressive degeneration were done using
Student’s t test.
Immunohistochemical studies
The mice were anesthetized with sodium pentobarbital
(60 mg/ml, i.p. (0.1 ml/100 g)) and perfused transcar-
dially with heparinized saline followed by 4 % parafor-
maldehyde (PFA) in 0.1 M phosphate-buffered saline,
pH 7.4. The brain and spinal cord were removed and
fixed in 4 % formalin for 5 days. They were processed
for immunohistochemical staining by dehydrating
through a series of increasing ethanol concentrations
(50, 70, to 100 %) followed by immersing in xylaxine to
enable paraffin embedding. Paraffin blocks with the
brain and spinal cord were prepared and sectioned using
a microtome at 8 μm. The sections were air dried over-
night before immunostaining. Each slide with three ser-
ial sections of the brain and spinal cord was immersed
in xylaxine to dewax the sections. The tissues were rehy-
drated through increasing ethanol concentrations and fi-
nally in distilled water before antigen retrieval in citrate
buffer for 5 min. The sections were washed and outlined
with a PAP pen before blocking for endogenous peroxid-
ase for 1 h. Non-specific antibody was blocked with goat
serum for 1 h. One serial section was incubated with
antibody for mGluR5 (Abcam) applied at 1:200 dilution,
while the adjacent section was incubated with IBA1 anti-
body (Abcam) at 1:100 dilution. The sections were incu-
bated with the respective antibodies overnight at 4 °C.
The negative control did not have the primary antibody.
On the following day, the sections were washed before
applying biotinylated goat anti-rabbit secondary antibody
for 1 h. After that, the slides were incubated in
streptavidin-HRP for 30 min. The antibody was detected
with the chromogen 3,3′-diaminobenzidine (DAB). The
secondary antibodies with developing reagents were pur-
chased from Millipore. The nuclei were stained with
hematoxylin. The sections were washed after each step
before subsequent application. The stained mGluR5
positive cells and IBA1 positive microglial cells were
viewed under a light microscope.
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Results
The binding potential (BPND) of [
18F]FPEB in the whole
brain of the base mice was 2.09 ± 0.36; in ALS mice at
stage 1, it was 3.13 ± 0.15 and at stage 3 3.85 ± 0.47 indi-
cating 49 ± 9 % increase from the base mice to ALS-type
mice and further enhancement of 23 ± 4 % during dis-
ease progression. In the individual brain areas, the high-
est increase was in the hippocampus being 115 ± 15 %
from base mice to ALS mice and further 30 ± 5 % during
degeneration. The corresponding values for the binding
potential in the striatum were 2.69 ± 0.13 in the base
mice, 5.61 ± 0.27 in ALS mice at stage 1, and 7.22 ± 1.31
at stage 3 indicating 108 ± 11 % increase from the base
mice to the ALS mice and 29 ± 5 % increase during pro-
gression of the disease. Correspondingly, the binding po-
tential in the cortex of the base mice was 1.17 ± 0.12, in
the ALS mice at stage 1 2.41 ± 0.13, and 2.88 ± 0.19 at
stage 3 indicating 105 ± 11 % increase from the base
mice and further increase of 19.5 ± 3 % during disease
progression (Figs. 1 and 2). The accumulation of
[11C]PBR28 was increased by 110 ± 33 % in the whole
brain during progression of the disease indicating signifi-
cant inflammatory process (Fig. 3). The accumulation of
[18F]FPEB was enhanced 6 % in thoracic spinal cord and
22 % in lumbar cord while [11C]PBR28 accumulation
was enhanced 89 and 264 %, respectively, in the same
areas during progression of the disease. Also, in the
lungs, [11C]PBR28 accumulation was increased by 204 %
indicating excessive inflammatory process. [18F]FPEB
accumulation was enhanced only 6 % in the lungs (Fig. 4).
The immunohistological studies verified enhanced mGluR5
expression and inflammatory response in the brain and
spinal cord (Fig. 5).
Discussion
Compared to the base mice, the mGluR5 expression was
significantly enhanced in the brain of ALS mouse model
especially in the hippocampus, striatum, and cortex as
well as in the averaged whole brain enhancing signifi-
cantly also during progression of the disease in the
hippocampus and cortex. Significant enhancement of
mGluR5 expression was observed also in the cervical
spinal cord during the disease progression. However,
[11C]PBR28, which is a marker for TSPO and micro-
glial activation, showed the most significant enhance-
ment in the brain and spinal cord during progression
of the disease. The enhancement in the whole brain
was 110+/33 %, five times more than averaged enhance-
ment of mGluR5 expression. In the spinal cord, the en-
hancement was from 89 to 264 % and in the lungs 204 %.
The difference between enhancements of mGluR5 expres-
sion and inflammatory response might be caused by the
excessive glutamate-induced excitotoxicity in the synapses
which may contribute to enhanced inflammatory pro-
cesses in CNS.
Concerning the imaging ligand [11C]PBR28, the accu-
mulation in the lungs might be affected by non-specific
binding, which has been reported for [11C]PBR28 in the
lungs [36]. In addition, TSPO has polymorphism that ef-
fects binding potential in vitro and in vivo in humans
[37]. In this experiment, we followed the same animals
with the same imaging procedures so even if the non-
Fig. 1 PET, CT, and fused PET/CT images illustrate anatomical distribution of [18F]FPEB, a mGluR5 imaging ligand in an ALS mouse. Separate
CT (left), PET (right bottom), and fused PET/CT (right above) images of an ALS mouse at stage 3. In the fused image, the sagittal slice (thickness
0.6 mm) shows enhanced accumulation of [18F]FPEB in brain, spinal cord, abdominal area, and bladder 60 min after administration of radioligand
(120 μCi iv). Coronal, sagittal, and axial views of the brain in the PET study show high accumulation in cortical areas. Crosshair in the images
illustrates the location of each slice. In these mice, we have observed progressively enhanced mGluR5 expression when the general health status
declined. The CT image demonstrates the level of spatial detection that can be achieved with the present imaging technology. We can accurately
detect and quantitate modulation of receptor binding and inflammatory response in small areas in spinal cord and brain
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specific binding or polymorphism effects on absolute
values, their effect on the difference between the values
is minimal.
Since inflammation can occur in any brain area, refer-
ence tissue model cannot be used to analyze [11C]PBR28
data. These data are presented as percent accumulation
of the injected radioactivity per tissue volume. The se-
lected regions of the interest are the same as for the
studies with [18F]FPEB. During the disease progression
from stage 1 to 3, inflammatory response increased five
times more than mGluR5 expression in the whole brain
providing strong evidence that inflammation can be
dependent on enhanced glutamatergic function. Since
mGlu5 receptors have primary postsynaptic location, the
enhanced binding potential values of mGluR5 may indi-
cate enhanced glutamate content in the synapse.
Cerebellum data cannot be used as a reference tissue
in the data analyses of [18F]FPEB in the spinal cord since
the transportation of the radioligand is not the same as
inside the brain, so expression was determined as a per-
cent of the injected dose in cubic centimeter.
Resolution of the microPET imager is 0.9 mm, which
will create errors in absolute values in quantification of
data in small brain areas because of the partial volume
effect. To minimize this issue, we have conducted longi-
tudinal imaging studies in the same animals to evaluate
functional changes and have used the same size for re-
gion of interest in consecutive studies. To be noted that
the resolution of the CT is 50 μm enabling us to localize
very tiny areas even in the spinal cord but when we
Fig. 3 PET and fused PET/CT images of the distribution of [11C]PBR28 accumulation in ALS mouse at the stage 3. Studies of inflammatory
response using [11C]PBR28 (240 μCi i.v.) were conducted in the same mouse as above (Fig. 1) 2 days after the study of mGluR5 expression. High
accumulation of [11C]PBR28 was seen in lungs, hindbrain, brain stem, and in different parts of spinal cord, indicating activated microglia and
expression of translocator protein (TSPO). In the mice, we observed fivefold higher enhancement of inflammatory response in brain stem and
cervical canal in progression of the disease than in modulation of mGluR5 expression in the same areas
Fig. 2 Quantitative distribution of [18F]FPEB in different brain areas in
the base mouse and ALS mouse at the stages 1 and 3. Comparison of
the binding of [18F]FPEB in the striatum, hippocampus, cortex, and
whole brain in base mice and ALS mice at the stages 1 and 3. It can
be seen that mGluR5 expression is highly increased in ALS mice
carrying SOD1-G93A gene compared to base mice and it is further
increased when the disease progressed. Of the individual brain areas,
the hippocampus has the highest increase between the base mice
and ALS mice and further the highest increase between stages 1 and
3 making the hippocampus area the most sensitive brain area for
glutamatergic modulation in ALS-type degeneration. Values for
binding potential (ND) were calculated based on reference tissue
model using cerebellar data as an input function [27, 33, 34]. Mean
values for binding potential were calculated from four base mice and
four ALS mice. Statistical analysis was done with student’s t test, and
significances are marked to the figure (*p < 0.05 = , **p < 0.01 = ,
and ***p < 0.001 = )
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record the radioactivity in that tiny area, the absolute
value will be underestimated.
The obtained values for excessive inflammation sup-
port the fast decline of the health status of these mice,
and the immunohistological studies verify the end point
data of enhanced mGluR5 expression and inflammation
in the brain and spinal cord.
Using the powerful imaging technology, we have con-
ducted imaging studies of mGluR5 expression and in-
flammatory response in SOD1 G93 mice and found
enhanced mGluR5 expression in several brain areas and
spinal cord with enhancement in 2 weeks follow-up
period (Figs. 1 and 2). We found also significantly en-
hanced accumulation of [11C]PBR28, marker for acti-
vated microglia, in hind brain, areas in spinal cord, and
the highest accumulation in the lungs (Figs. 3 and 4).
The enhanced expression of mGluR5 in the brain of
ALS mice support the regional inflammation observed
in ALS patients using [11C]PBR28 as an imaging ligand
[38]. The regional areas of the brain in these human
studies were determined by the simultaneous anatomical
MR imaging. These studies also showed that [11C]PBR28
binding was enhanced in all brain areas of ALS patients
compared to age-matched controls.
The studies on ALS pathology based on glutamatergic
function and inflammatory response using the highly in-
novative in vivo imaging technology recently developed
by our team [27, 30] show significant local pathophysio-
logical changes that can be targeted with therapeutic ap-
proaches. The results of these exploratory experiments
can be immediately extended to ALS patients to enhance
early diagnosis and follow therapeutic response and even
Fig. 5 Immunohistochemical studies of expression of mGluR5 and IBA1 in ALS brains and spinal cord. mGluR5 and IBA1 expression in the brain
(a) and spinal cord (b) of ALS mice showed the active inflammation occurring in these regions following neurotransmitter release. mGluR5 was
highly expressed in the entire brain, primarily in the gray matter. In the caudal diencephalon, mGluR5 expression was found in the striatum and
hippocampus regions. Microglia which was stained by IBA1 was expressed at sites consisting of capillaries and neurons in these regions. In some
areas, the microglial cell bodies were enlarged, while in some areas, the microglia were elongated. Both these morphological forms of microglia
were indicative of inflammation. mGluR5 was expressed throughout the spinal cord and IBA1 was expressed in the gray matter as an indication
of inflammatory processes
Fig. 4 Quantitative analysis of modulation of mGluR5 expression
and inflammatory response in the spinal cord and lungs during
progression of the disease. Comparison of mGluR5 expression and
inflammatory response during progression of ALS-type degeneration
in different parts of spinal cord and lungs shows enhancement in
the accumulation of [18F]FPEB but significantly higher enhancement
of [11C]PBR28 accumulation in the lumbar cord and lungs. The selected
region of interest was the same for both studies. Quantitative values
were calculated as percent of the injected activity in the tissue volume
(cm3) since no reference tissue method can be used for inflammatory
processes as well as no brain-related input function for peripheral
mGluR5 expression. Mean values for accumulation were calculated
from four base mice and four ALS-mice. Statistical analyses were
done with student’s t test, and significances are marked to the figure
(*p < 0.05 = , **p < 0.01 = , and ***p < 0.001 = )
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to design more effective therapeutic approaches. Imaging
ligands of mGluR5 ([18F]FPEB) and inflammatory re-
sponse ([11C]PBR 28) are already in human use, so the
technical aspects for transition are immediate. It is not-
able that there have been several failed clinical trials in
ALS. One contributing matter for this might be that pre-
viously, there has been limitation to spatially and tem-
porally record involved pathophysiological mechanisms.
Conclusions
With in vivo PET imaging studies, we have shown that
SOD1-G93A gene will significantly enhance mGluR5 ex-
pression in the brain and spinal cord in ALS mouse
model. In addition, mGluR5 expression increased in the
whole brain significantly and moderately in the spinal
cord during progression of the disease. Inflammation in-
creased in all brain areas and spinal cord up to fivefold
more than mGluR5 expression during progression of the
disease indicating the excitatory role of excessive glu-
tamate may contribute or accelerate of inflammation in
ALS pathology.
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